Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Vosoughi A, Zhang T, Shohdy KS, Vlachostergios PJ, Wilkes DC, Bhinder B, et al. Common germline-somatic variant interactions in advanced urothelial cancer. Nat Commun. 2020;11(1):6195.

Braunstein MJ, Petrova-Drus K, Rosenbaum CA, Jayabalan DS, Rossi AC, Salvatore S, et al. Plasma Cell Myeloma Presenting With Amyloid-Laden Crystal-Negative Histiocytosis. Am J Clin Pathol. 2020;154(6):767-775.

Casiraghi N, Orlando F, Ciani Y, Xiang J, Sboner A, Elemento O, et al. ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA. Bioinformatics. 2020;36(9):2665-2674.

Goyal A, Patel AP, Dilcher TL, Alperstein SA. Effects of Implementing the Dual Papanicolaou Test Interpretation of ASC-H and LSIL Following Bethesda 2014. Am J Clin Pathol. 2020;154(4):553-558.

Reynders M, Matsuura BS, Bérouti M, Simoneschi D, Marzio A, Pagano M, et al. PHOTACs enable optical control of protein degradation. Sci Adv. 2020;6(8):eaay5064.

Prutsch N, Gurnhofer E, Suske T, Liang HC, Schlederer M, Roos S, et al. Correction: Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. Leukemia. 2020;34(11):3105.

Cheleuitte-Nieves C, Heselpoth RD, Westblade LF, Lipman NS, Fischetti VA. Searching for a Bacteriophage Lysin to Treat in Immunocompromised Mice. Comp Med. 2020;70(4):328-335.

Bhargava HK, Leo P, Elliott R, Janowczyk A, Whitney J, Gupta S, et al. Computationally Derived Image Signature of Stromal Morphology Is Prognostic of Prostate Cancer Recurrence Following Prostatectomy in African American Patients. Clin Cancer Res. 2020;26(8):1915-1923.

Schatz-Siemers N, Chen Y-, Chen Z, Wang D, Ellenson LH, Du Y-. Expression of the Receptor for Hyaluronic Acid-Mediated Motility (RHAMM) in Endometrial Cancer is Associated With Adverse Histologic Parameters and Tumor Progression. Appl Immunohistochem Mol Morphol. 2020;28(6):453-459.

Wang Q, Jia S, Wang D, Chen X, Kalvakolanu DV, Zheng H, et al. A Combination of BRD4 and HDAC3 Inhibitors Synergistically Suppresses Glioma Stem Cell Growth by Blocking GLI1/IL6/STAT3 Signaling Axis. Mol Cancer Ther. 2020;19(12):2542-2553.